A pilot study of recombinant interleukin‐2 for treatment of chronic hepatitis C
M Pardo, I Castillo, H Oliva, A Fernandez‐Flores, R Barcena, M A de Peuter, V Carreno – 30 December 2003 – The optimal and safer interleukin‐2 (IL‐2) dose for treatment of chronic hepatitis C virus (HCV) infection has been studied in 33 HCV‐RNA positive patients with chronic hepatitis C. Patients were randomly allocated to receive 5 days per week during 12 weeks IL‐2 doses of: 0.9 MIU (n = 10), 1.8 MIU (n = 10), or 3.6 MIU (n = 13). After 12 weeks, responder patients stopped treatment, whereas nonresponders received 12 additional weeks of IL‐2 at the next higher dose: 1.8, 3.6, or 5.4 MIU.